Antibody was affinity purified using an epitope specific to BRCA2 immobilized on solid support. The epitope recognized by A300-005A maps to a region between residue 3350 and the C-terminus (residue 3418) of human Breast Cancer Gene 2 using the numbering given in entry NP_000050.1 (GeneID 675). Immunoglobulin concentration was determined by extinction coefficient: absorbance at 280 nm of 1.4 equals 1.0 mg of IgG.
BRCA1/BRCA2-containing complex, subunit 2, BRCC2, breast and ovarian cancer susceptibility gene, early onset, breast and ovarian cancer susceptibility protein 2, breast cancer 2 tumor suppressor, breast cancer 2, early onset, breast cancer type 2 suscepti
between 3350 and C-term
2 - 8°C
Detection of human BRCA4 by western blot. Samples: Whole cell lysate (50 µg) from HEK293T, OVCAR-3, Hep-G2, K-562, Jurkat, HeLa, U2OS, and MCF-7 cells prepared using NETN lysis buffer. Antibody: Rabbit anti-BRCA4 antibody A300-005A (lot A300-005A-4) for WB at 0.1 µg/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.
Detection of human BRCA2 by western blot of immunoprecipitates. Samples: Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from HEK293T cells prepared using NETN lysis buffer. Antibodies: Rabbit anti-BRCA2 antibody A300-005A (lot A300-005A-4) used for IP at 6 µg per reaction. BRCA2 was also immunoprecipitated by a previous lot of this antibody (lot A300-005A-3). For blotting immunoprecipitated BRCA2, A300-005A was used at 0.1 µg/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.